- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Roche Shuffle Keeps Focus on Personalized Care
The departure of Pascal Soriot from Roche’s pharmaceutical division to the helm of rival AstraZeneca comes as a surprise, but the move isn’t likely to leave a hole among the higher ranks of the Swiss drug maker.
Roche veteran Daniel O’Day, who was tapped to replace Mr. Soriot as the new head of the Roche’s flagship pharmaceutical division, is well-equipped for the job. He’s held various positions at the unit since 1987 and spent his entire career at Roche, including postings in the U.S. and Japan. Most recently, Mr. O’Day, an American national, spent six years at Roche’s diagnostics division, leading it as chief operating officer since 2010.
Read the full story: http://tinyurl.com/9e2z5px
Source: The Wall Street Journal
New Insights on Breast Cancer Outcomes Among Sexual, Gender Minorities
December 7th 2023Despite there being a great demand for data collection on sexual orientation and gender identity in the cancer space, individuals who identify as a sexual and gender minority remain poorly represented.
Read More
Gestational Diabetes Is a Key Population Health Opportunity
December 7th 2023Diagnosing and treating gestational diabetes can have long-term positive effects on the health of the mother and the baby, warranting a distinct focus on the condition, according to an Institute for Value-Based Medicine® event held in Cleveland, Ohio.
Read More
Refining Precision Prevention for Benign Breast Disease
December 7th 2023Many questions remain surrounding accurately classifying the risk of developing invasive breast cancer associated with the benign breast disease diagnoses of nonproliferative lesions and proliferative changes without atypia.
Read More
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
